The value of (−7, −5)pro‐prostate‐specific antigen and human kallikrein‐2 as serum markers for grading prostate cancer
- 25 March 2004
- journal article
- clinical trial
- Published by Wiley in BJU International
- Vol. 93 (6), 720-724
- https://doi.org/10.1111/j.1464-410x.2003.04733.x
Abstract
To assess the value of the precursor form (-7,5pro) of prostate-specific antigen (PSA) and human kallikrein-2 (hK2) for detecting and grading prostate cancer, as better serum markers with improved specificity are needed in men with lower ranges of total (t)PSA. tPSA, free PSA (fPSA), the precursor (-7,5)proPSA and hK2 were measured in a subset of participants of the European Randomised Study of Screening of Prostate Cancer. In a pilot study, sera from 143 men biopsied but with no prostate cancer, 142 with BPH, and 146 with prostate cancer were analysed to determine the relative value of serum markers for differentiating between the groups. Then, in 141 men with prostate cancer who had a radical prostatectomy, these serum markers were related to the pathological grading to analyse their value as prognostic variables. Levels of (-7,5)proPSA, hK2 and fPSA could be used to distinguish between BPH and cancer, but proPSA and hK2, alone or combined, did not improve the specificity of fPSA for discriminating BPH and cancer. There was also no correlation between these serum markers and pathological tumour grade. The clinical effect of using (-7,5)proPSA or hK2 for detecting and grading prostate cancer remains limited.Keywords
This publication has 19 references indexed in Scilit:
- Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysisUrology, 2003
- Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor featuresUrology, 2002
- Free prostate-specific antigen in serum is becoming more complexUrology, 2002
- How accurately does prostate biopsy Gleason score predict pathologic findings and disease free survival?The Prostate, 2001
- Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml)The Prostate, 2001
- COMPLEXED PROSTATE SPECIFIC ANTIGEN PROVIDES SIGNIFICANT ENHANCEMENT OF SPECIFICITY COMPARED WITH TOTAL PROSTATE SPECIFIC ANTIGEN FOR DETECTING PROSTATE CANCERJournal of Urology, 2000
- Evaluation of the Digital Rectal Examination as a Screening Test for Prostate CancerJNCI Journal of the National Cancer Institute, 1998
- STABILITY OF FREE AND TOTAL PROSTATE SPECIFIC ANTIGEN IN SERUM FROM PATIENTS WITH PROSTATE CARCINOMA AND BENIGN HYPERPLASIAJournal of Urology, 1998
- The Free-To-Total Prostate Specific Antigen Ratio Improves the Specificity of Prostate Specific Antigen in Screening for Prostate Cancer in the General PopulationJournal of Urology, 1997
- The Free-to-Total Serum Prostate Specific Antigen Ratio for Staging Prostate CarcinomaJournal of Urology, 1997